. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: J Immunol. 2014 Jul 21;193(5):2317–2329. doi: 10.4049/jimmunol.1303223

Table 4.

GMCSF-MOG exhibited inhibitory activity when included in a CFA emulsion

Included in CFA emulsion^a	Incidence of EAE	Mean cumulative score	Median cumulative score	Mean maximal score	Median maximal score	% weight loss
(a) GMCSF-MOG + MOG35-55	3 of 6	15.7 ± 19.3	7.8	1.2 ± 1.5	0.5	4.4%
(b) GMCSF-MOG	1 of 6	1.1 ± 2.7	0.0	0.2 ± 0.4	0.0	4.3%
(c) MOG35-55	6 of 6	79.2 ± 36.6	83.5	3.7 ± 0.5	4.0	18.9%
(d) GMCSF-MOG + MOG	5 of 6	47.5 ± 33.7	40.5	2.8 ± 1.4	3.0	9.3%
(e) GMCSF-MOG	2 of 6	10.5 ± 16.4	0.0	0.8 ± 1.3	0.0	−1.6%
(f) MOG35-55	7 of 7	136.7 ± 10.9	142.0	4.0 ± 0.0	4.0	20.9%

(a–c) C57BL/6 mice were immunized on day 0 with 75 nmole of MOG35-55 in CFA (c), with 1 nmole of GMCSF-MOG in CFA (b), or a mix of 75 nmole of MOG35-55 and 1 nmole of GMCSF-MOG in CFA (a). All mice were given i.p. injections of Pertussis toxin on days 0 and 2. Data analysis represented the time course from day 0 through the end of the experiment on day 41. (c) versus(a) and (b); cumulative scores, p = 0.002, p < 0.001; maximal score, p = 0.002, p < 0.001; weight loss, p = 0.068, p = 0.005.

(d–f) B cell-deficient mice were immunized on day 0 with 75 nmole of MOG35-55 in CFA (c), with 2 nmole of GMCSF-MOG in CFA (b), or a mix of 75 nmole of MOG35-55 and 2 nmole of GMCSF-MOG in CFA (a). All mice were given i.p. injections of Pertussis toxin on days 0 and 2. Data analysis represented the time course from day 0 through day 50. Average daily weight loss was calculated as the average of daily body weight measurements from day 10 until the end of experiment, subtracted from the 100% maximal body weight. (f) versus(d) and (e); cumulative scores, p < 0.001, p < 0.001; maximal score, p = 0.002, p < 0.001; maximal weight loss, ns, p < 0.001; average weight loss; p = 0.018, p < 0.001;